NCT05581823已完成1 期
A Phase 1, Open-label, Fixed-sequence, Crossover Trial to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Induction by Carbamazepine on the Steady-state Pharmacokinetics of Tavapadon in Healthy Adult Participants
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Maximum Observed Plasma Concentration (Cmax) of Tavapadon
研究概览
简要总结
The primary purpose of this study is to evaluate the effect of carbamazepine, a strong CYP3A4 inducer, on the steady-state pharmacokinetics (PK) of tavapadon in healthy adult participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Women of nonchildbearing potential and men 18 to 55 years, inclusive, at the time of signing the informed consent form (ICF).
- •Sexually active men with a pregnant or nonpregnant partner of childbearing potential must agree to use a condom during the trial and for 90 days after the last dose of carbamazepine. In addition, male participants should not donate sperm for a minimum of 90 days following the last dose of carbamazepine.
- •Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, ECG, vital sign measurements, and laboratory test results, as evaluated by the investigator.
- •Body mass index of 18.5 to 32.0 kilograms per square meter (kg/m^2), inclusive, and total body weight >50 kg (110 pounds [lbs]) at Screening.
- •Capable of giving signed informed consent as described in the full protocol, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.
排除标准
- •"Yes" responses for any of the following items on the C-SSRS (within past 6 months):
- •Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan)
- •Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) "Yes" responses for any of the following items on the C-SSRS (within past 2 years):
- •Any of the Suicidal Behavior items (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior).
- •Serious risk of suicide in the opinion of the investigator is also exclusionary.
- •Participants shown to carry or be positive for human leukocyte antigen (HLA)-B*1502 or HLA-A*
- •Use of prohibited medication prior to randomization (5 half-lives) or likely to require prohibited concomitant therapy (e.g., prescription and over-the-counter medications, herbal medications, vitamins, and supplements) during the trial. CYP3A4 inhibitors and inducers are prohibited from 30 days prior to signing of the ICF through the end of the trial.
- •Recent monoamine oxidase inhibitors (MAO-I) use (in the last 28 days) as it increases the risk for hypersensitivity and bone marrow suppression from carbamazepine.
- •Prior carbamazepine use that was discontinued for tolerability or adverse events, including a clinically significant decrease in platelets, white blood cells or hemoglobin.
- •Platelets, white blood cell count, or hemoglobin <lower limit of normal (LLN).
- •Estimated glomerular filtration rate <90 milliliters per minute (mL/min)/1.73 m^2, as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
- •NOTE: Other protocol-defined Exclusion criteria may apply.
研究组 & 干预措施
Tavapadon Followed by Tavapadon + Carbamazepine
Experimental
Participants will receive oral tavapadon tablets titrated up to a steady-state dose from Day 1 to Day 14. From Day 15, participants will receive oral carbamazepine tablets titrated up to a steady-state dose along with oral tavapadon tablets, up to Day 30.
干预措施: Tavapadon (Drug)
Tavapadon Followed by Tavapadon + Carbamazepine
Experimental
Participants will receive oral tavapadon tablets titrated up to a steady-state dose from Day 1 to Day 14. From Day 15, participants will receive oral carbamazepine tablets titrated up to a steady-state dose along with oral tavapadon tablets, up to Day 30.
干预措施: Carbamazepine (Drug)
结局指标
主要结局
Maximum Observed Plasma Concentration (Cmax) of Tavapadon
时间窗: Pre-dose and at multiple timepoints post-dose up to Day 31
Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Tavapadon
时间窗: Pre-dose and at multiple timepoints post-dose up to Day 31
次要结局
- Number of Participants With Adverse Events (AEs) and AEs by Severity(Day 1 up to Day 36)
- Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Values(Up to Day 31)
- Number of Participants with Clinically Significant Changes in Vital Sign Values(Up to Day 31)
- Number of Participants with Clinically Significant Changes in Clinical Laboratory Assessments(Up to Day 30)
- Number of Participants with Clinically Significant Changes in Physical and Neurological Examination Results(Up to Day 31)
- Changes in Suicidality Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)(Up to Day 31)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy AdultsHealthyNCT06646042Pfizer12
已完成
1 期
A Study of the Effect of Carbamazepine on the Pharmacokinetics of Paliperidone Extended Release (ER) in Patients With Schizophrenia or Bipolar I DisorderBipolar DisorderSchizophreniaNCT00892125Johnson & Johnson Pharmaceutical Research & Development, L.L.C.64
已完成
1 期
A Study of Ponesimod in Healthy Adult ParticipantsHealthyNCT05552196Janssen Pharmaceutica N.V., Belgium28
已完成
1 期
A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy VolunteersHealthy VolunteerNCT01629368Hoffmann-La Roche16
已完成
1 期
A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult ParticipantsHealthyNCT04330248Johnson & Johnson Pharmaceutical Research & Development, L.L.C.15